R Squared’s Cytokinetics CYTK Stock Holding History

R Squared’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,830	Closed	-$133K	–	600
2024 Q4	$133K	Buy	+2,830	New	+$147K	0.13%	197

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

R Squared's CYTK Position: Q1 2025 in Review

R Squared sold out of Cytokinetics (CYTK) in Q1 2025, closing a stake of 2,830 shares — an estimated $133K sold.

R Squared first reported a position in CYTK in Q4 2024 and held it in 1 quarter. The position peaked at $133K in Q4 2024. 355 funds tracked by Wall St. Rank hold CYTK as of Q1 2025.

R Squared reported no remaining Cytokinetics position as of Q1 2025 after selling out during the quarter.
R Squared sold 2,830 Cytokinetics shares in Q1 2025, an estimated $133K.
R Squared first reported a position in Cytokinetics in Q4 2024 and held it in 1 quarter.
R Squared's Cytokinetics position peaked at $133K in Q4 2024.
355 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.